Stockwinners Market Radar for March 04, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:57 EST Bank of Montreal cuts prime lending rate to 3.45% from 3.95% - BMO Bank of Montreal announced that it is decreasing its CDN$ prime lending rate from 3.95% to 3.45%, effective March 5, 2020.

18:49 EST Fly Intel: After Hours Movers - UP AFTER EARNINGS: Marvell Technology (MRVL) up 9.3%... American Eagle (AEO) up 5.5%... Ping Identity (PING) up 2.3%. DOWN AFTER EARNINGS: Guidewire (GWRE) down 12.9%... Veritone (VERI) down 10.1%... Zoom Video (ZM) down 6.2%... Comtech Telecom (CMTL) down 5.6%... WideOpenWest (WOW) down 4.2%... Splunk (SPLK) down 3.8%... TTEC Holdings (TTEC) down 1.6%. ALSO LOWER: Finjan Holdings (FNJN) down 5.6% after announcing plans to remain independent following review... Evoqua Water (AQUA) down 2.0% after equity offering. Movers as of 18:30ET.

18:44 EST Dollar Tree CEO: Retail is off the charts right now - In an interview on CNBC's Mad Money, Dollar Tree CEO Gary Philbin said, "We don't know the future of the coronavirus, but we feel like things are turning back to normal on the supply side. We'll be faced with headwinds from tariffs through the first half of the year."

18:36 EST CIBC cuts prime lending rate to 3.45% from 3.95% - CIBC announced that it is lowering its Canadian prime lending rate by 50 basis points from 3.95% to 3.45%, effective Thursday, March 5, 2020.

18:31 EST Fastly director sells 126.3K shares of common stock - In a regulatory filing, Fastlydisclosed that its director Sunil Dhaliwal sold 126.3K shares of common stock on March 2nd and March 4th. The total transaction size was $2.6M.

18:26 EST IBM cancels in-person Think 2020 event over coronavirus concerns - IBM said that it is canceling its upcoming Think 2020 event in San Francisco amid growing coronavirus fears. On its Think 2020 website, IBM said that the conference will be recreated as a global, digital-first event, to still be held on May 5-7. "The health of IBM's clients, employees and partners is our primary concern," the company said. "In light of global precautions for the COVID-19 Coronavirus, and building upon recommendations from the World Health Organization, IBM is taking a new approach to its signature events." Reference Link

18:15 EST TD Canada Trust cuts prime lending rate to 3.45% from 3.95% - TD Canada Trust announced that it has decreased its prime lending rate by 50 basis points to 3.45%, effective March 5, 2020.

17:37 EST Slack Technologies officer David Schellhase sells almost $606K in company shares - Slack Technologies officer David Schellhase disclosed in a filing that he had sold 22,666 shares of company stock at an avergae price of $26.73 per share on March 2. The total transaction value of the sale was $605,862.

17:12 EST TTEC Holdings raises semi-annual cash dividend 6.3% to 34c per share - TTEC Holdings announced that on February 27, 2020 its Board of Directors declared a cash dividend of 34c per common share to be paid on April 16, 2020 to shareholders of record as of April 1, 2020. This semi-annual dividend represents a 6.3% increase over the dividend paid in October 2019 and 13.3% increase over the dividend paid in April 2019.

17:05 EST Berry Global announces investment to boost production capacity of UHP films - Berry Global Group announced that to address rising demand it is investing approximately $30 million to increase production capacity for ultra-high performance stretch films. The investment is allocated for new lines and upgrades to existing assets in nine of the Company's North American locations that currently manufacture stretch film.The projects are set to begin immediately and are expected to be completed by April 2021. "Stretch film customers continue to seek palletization films that decrease breakage, damage and loss, while reducing wrapping cost and providing sustainable value," said Mike Hill, President of Berry's Engineered Materials Division. "Today's announcement is in direct alignment with Berry's commitment to strategically invest in advantaged products within the Engineered Materials Division."

17:01 EST General Dynamics raises dividend 7.8%, announces 10M share repurchase plan - The board of directors of General Dynamics declared a regular quarterly dividend of $1.10 per share on the company's common stock, payable May 8 to shareholders of record on April 10. This is the 23rd consecutive annual dividend increase authorized by the General Dynamics board, and represents a 7.8% increase over last year's dividend. The board also provided management with the authority to repurchase an additional 10M shares of the company's issued and outstanding common stock on the open market.

16:47 EST RBC Royal Bank cuts prime rate to 3.45% from 3.95% - RBC Royal Bank decreased its prime rate by 50 basis points to 3.45% from 3.95%, effective March 5, 2020.

16:36 EST Asur reports total February passenger traffic up 12.7% y/y - Asur Airports announced that total passenger traffic for February 2020 increased 12.7% when compared to February 2019. Passenger traffic increased 9.7% in Mexico, 16.1% in Puerto Rico and 19.5% in Colombia. This announcement reflects comparisons between February 1 through February 29, 2020, and from February 1 through February 28, 2019. Please note that figures for February 2020 include an extra day of operations. Transit and general aviation passengers are excluded for Mexico and Colombia.

16:33 EST Canopy Growth to close two Canadian greenhouses, record Q4 charges - Canopy Growth Corporation announced that the company plans to close its facilities in Aldergrove and Delta, British Columbia, resulting in the elimination of approximately 500 positions. In addition, the company no longer plans to bring a third greenhouse online in Niagara-on-the-Lake, Ontario. These actions are part of the company's effort to align supply and demand while improving production efficiencies over time. The greenhouses in B.C. account for approximately 3 million square feet of licensed production space and were put into commission, beginning in February 2018, after a period of phased retrofitting to help Canopy Growth scale up to supply the new Canadian adult-use market. Nearly 17 months after the creation of the legal adult-use market, the Canadian recreational market has developed slower than anticipated, creating working capital and profitability challenges across the industry. Additionally, federal regulations permitting outdoor cultivation were introduced after the Company made significant investments in greenhouse production. The company now operates an outdoor production site to allow for more cost-effective cultivation, which will play an important role in meeting demand on certain products that rely on cannabis extracts. Following an organizational strategic review of production capacity and forecasted demand, the company announced that these facilities in Aldergrove and Delta, British Columbia are no longer essential to its cultivation footprint. Along with this announcement, the company expects, based upon information currently available to management, to record estimated pre-tax charges of approximately $700M-$800M in the quarter ending March 31, 2020 reflecting today's announcement as well as additional changes related to its organizational and strategic review.

16:31 EST Electromed announces CFO Brock to pursue other opportunities - Electromed announced that CFO Jeremy Brock has elected to pursue other opportunities and the company and Brock have established a transition plan. Brock will continue in the role of CFO until July 1. Electromed has commenced a national search process to identify and recruit its next CFO.

16:22 EST Apache names Clay Bretches as executive VP of operations - Apache announced details regarding its new organizational structure and key leadership roles. As announced in October 2019, the company has undertaken a comprehensive redesign of its organizational structure and operations to further align its work processes and cost structure with long-term planned activity levels. The new design will enable more effective management of Apache's diverse portfolio of assets through centralized teams organized around three functional pillars: Operations, Development and Exploration. Clay Bretches was named executive vice president of Operations, and David Pursell was named executive vice president of Development. The leader of exploration will be named following the completion of an ongoing search. Mr. Bretches will continue to serve in his role as CEO and president of Altus Midstream Company, a controlled subsidiary of Apache. All three executives will report directly to Apache CEO and president John J. Christmann IV. "Our new organization, built on central pillars of Operations, Development and Exploration, will enable us to manage our assets more efficiently while enhancing our strategy of finding and developing new, low-cost resources. We will be able to more effectively deploy capital and human resources, respond to market conditions, and retain and advance top talent," said Christmann. "Clay Bretches and Dave Pursell bring tremendous leadership and technical experience to their respective roles and have been an integral part of the strategic redesign of the organization."

16:19 EST Colliers Canada promotes Brian Rosen to CEO - Colliers International announced that Brian Rosen, currently COO Canada, will succeed David Bowden as CEO Canada, effective March 31. Bowden will transition to a new role as CEO, Colliers Real Estate Strategy & Consulting, reporting into Rosen. In his new position, Bowden will integrate Colliers' existing consulting practices into a national Real Estate Strategy & Consulting entity.

16:16 EST Saga Communications raises quarterly dividend to 32c from 30c per share - The dividend will be paid on April 10 to shareholders of record on March 16.

16:16 EST Urban Edge announces $200M share repurchase - Urban Edge announced that the board has authorized a share repurchase program for up to $200 million of the company's common shares.

16:13 EST Marvell up 10% to $24.90 after Q4 results beat estimates

16:12 EST ViaSat, Blacktree partner to provide services to Australian Defence Force - Viasat signed a Strategic Alliance Agreement with Blacktree Technology, an Australian-based communications systems design and integration company, in November 2019. The SAA will enable Viasat and Blacktree to meet the needs of the Australian Defence Force requirements, by providing in-country manufacturing and support services for Ultra High Frequency satellite communications systems.

16:09 EST Marvell CEO says Q1 guidance reflects 'impacts we are aware of so far' - "Marvell delivered fourth quarter revenue above the mid-point of guidance with solid results from both our networking and storage businesses. Our guidance for the first quarter of fiscal 2021 reflects the reduction of approximately 5 percent of revenue to account for coronavirus impacts we are aware of so far," said Matt Murphy, Marvell's President and CEO. "Our customer and design win traction in the wireless infrastructure market continues to grow and Nokia announced an expanded relationship with Marvell to develop multiple generations of leading 5G silicon solutions. We also announced the extension of our long-term collaboration with Samsung on the radio access network. Marvell's first quarter guidance takes into account the U.S. Government's export restriction on certain Chinese customers. Given the ongoing uncertainty associated with the coronavirus, we also have temporarily widened the guidance range on revenue."

16:08 EST Marvell reports Q4 adjusted gross margin 62.3%

16:02 EST Align Technology acquires exocad for EUR376M in cash - Align Technology announced that it has signed a definitive agreement to acquire privately held exocad Global Holdings GmbH for approximately EUR376M in cash. exocad is a global leader in the dental CAD/CAM software market and offers fully integrated workflows to dental labs and dental practices via a broad customer base of partners, and resellers in over 150 countries. The acquisition of exocad strengthens the Align digital platform that delivers innovative tools and features for diagnostic, restorative, implant, and orthodontic workflows. The acquisition brings exocad's expertise in restorative dentistry, implantology, guided surgery, and smile design to the Align technology portfolio, extending Align's Invisalign and iTero digital solutions and paving the way for new, seamless cross-discipline dentistry in lab and at chairside. exocad also broadens Align's platform reach in digital dentistry with close to 200 partners and more than 35,000 licenses installed worldwide. Under the terms of the agreement, Align will pay approximately EUR376M in cash to acquire exocad, which is majority owned by Carlyle Europe Technology Partners. The acquisition is expected to close during Q2. Align anticipates that the acquisition of exocad is expected to be gross margin accretive, reflecting the strength of exocad's software business. The company expects GAAP EPS to be dilutive for FY20, due to acquisition-related costs.

16:01 EST GM unveils new Ultium batteries to power global EV platform - General Motors said it is gathering hundreds of employees, dealers, investors, analysts, media and policymakers to share details of its strategy to grow the company's electric vehicle sales quickly, efficiently and profitably. The heart of GM's strategy is a modular propulsion system and a highly flexible, third-generation global EV platform powered by proprietary Ultium batteries, the car maker said. They will allow the company to compete for nearly every customer in the market today, whether they are looking for affordable transportation, a luxury experience, work trucks or a high-performance machine. "Thousands of GM scientists, engineers and designers are working to execute an historic reinvention of the company," said GM President Mark Reuss. "They are on the cusp of delivering a profitable EV business that can satisfy millions of customers." Ultium energy options range from 50 to 200 kWh, which could enable a GM-estimated range up to 400 miles or more on a full charge with 0 to 60 mph acceleration as low as 3 seconds. Motors designed in-house will support front-wheel drive, rear-wheel drive, all-wheel drive and performance all-wheel drive applications. Ultium-powered EVs are designed for Level 2 and DC fast charging. Most will have 400-volt battery packs and up to 200 kW fast-charging capability while our truck platform will have 800-volt battery packs and 350 kW fast-charging capability. Chevrolet, Cadillac, GMC and Buick will all be launching new EVs starting this year. The next new Chevrolet EV will be a new version of the Bolt EV, launching in late 2020, followed by the 2022 Bolt EUV, launching Summer 2021. The Bolt EUV will be the first vehicle outside of the Cadillac brand to feature Super Cruise, the industry's first true hands-free driving technology for the highway, which GM will expand to 22 vehicles by 2023, including 10 by next year. The Cruise Origin, a self-driving, electric shared vehicle, shown to the public in January 2020 in San Francisco, was the first product revealed using GM's third generation EV platform and Ultium batteries. Next will be the Cadillac Lyriq luxury SUV in April. Details about its launch will be shared then. The reveal of the Ultium-powered GMC HUMMER EV will follow on May 20. Production is expected to begin in Fall 2021 at GM's Detroit-Hamtramck assembly plant, GM's first assembly plant 100 percent dedicated to EV production.

14:59 EST Meet Group jumps 20% after Reuters report on nearing takeover - Shares of Meet Group are up about 20% after Reuters said that German broadcaster ProSiebenSat.1 Media's e-commerce unit, NuCom Group, is close to a deal to acquire the dating app developer. A deal, which could value the U.S. company at more than $500M, could be finalized as early as Thursday, said Reuters, citing people familiar with the matter. Following the report, Meet Group shares are up $1.15, or 20.8%, to $6.69.

14:50 EST MeetMe trading halted, volatility trading pause

14:41 EST Telecom Italia and Google launch strategic partnership - Telecom Italia (TIIAY),TIM, and Google (GOOG) announce the signing of their official agreement for a joint technology collaboration, following the Memorandum of Understanding (MoU) signed in November 2019 between both companies. TIM and Google Cloud have agreed to work together to build innovative Public, Private and Hybrid Cloud services for TIM's expanding technology services portfolio. As a result of this collaboration, TIM intends to extend its leadership in Cloud and Edge Computing services. TIM aims to boost the growth of its revenues from technology services, with the objective of reaching 1 billion euros in revenues and 0.4 billion euros in EBITDA by 2024. TIM's CEO, Luigi Gubitosi, stated: "This strategic partnership with Google places TIM among the Italian key players in Cloud and Edge computing, two markets that will become more and more central with the deployment of 5G technology and Artificial Intelligence. By choosing to join forces with a recognised global technological and innovation leader we confirm our commitment to promote and accompany Italy's digital progress." Reference Link

14:27 EST Google taps former Sony Santa Monica Studio head to run new Stadia team - Jade Raymond, vice president and head of Google's (GOOG) Stadia Games and Entertainment, said in a blog post that Stadia is adding a new Stadia Games and Entertainment studio in Playa Vista, California, which will be led by an industry veteran, Shannon Studstill. "I've been a fan of Shannon's for a long time, and have admired her award-winning work leading Sony's (SNE) Santa Monica Studio and the industry defining franchises like God of War that have won fans all over the world," Raymond said. "She has an extensive background in product development and creative leadership, but most importantly, she's a visionary who, as the Studio Director, will lead and inspire the Playa Vista teams. We're thrilled to welcome her to the Stadia family!" The Fly notes that Studstill headed the Sony Santa Monica Studio when it developed 2018's "God of War."

14:01 EST Huntington Bancshares decreases prime rate to 4.25% - Huntington Bancshares announced that its prime rate is decreasing from 4.75% to 4.25%, effective March 4.

13:33 EST FDA requires Boxed Warning for mental health side effects of Singulair - The U.S. Food and Drug Administration announced it is strengthening existing warnings about serious behavior and mood-related changes with montelukast - Singulair and generics - which is a prescription medicine for asthma and allergy. "We are taking this action after a review of available information led us to reevaluate the benefits and risks of montelukast use. Montelukast prescribing information already includes warnings about mental health side effects, including suicidal thoughts or actions; however, many health care professionals and patients/caregivers are not aware of the risk. We decided a stronger warning is needed after conducting an extensive review of available information and convening a panel of outside experts, and therefore determined that a Boxed Warning was appropriate. Because of the risk of mental health side effects, the benefits of montelukast may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with other medicines. For allergic rhinitis, also known as hay fever, we have determined that montelukast should be reserved for those who are not treated effectively with or cannot tolerate other allergy medicines. For patients with asthma, we recommend that health care professionals consider the benefits and risks of mental health side effects before prescribing montelukast," the FDA stated in a notice posted to its website.Reference Link

13:22 EST Class 8 net truck orders in February were 14,100 units, down 16% from last year - Preliminary NA Class 8 net orders in February were 14,100 units, down 18% from January and 16% lower than an easy year-ago comparison. February's Classes 5-7 net orders rose to an 11-month high 22,200 units, up 12% from January, but down 12% from a very strong year-ago comparison, according to ACT Research. Complete industry data for February, including final order numbers, will be published by ACT Research in mid-March. Publicly traded companies in the space include ArcBest (ARCB), J.B. Hunt (JBHT), Knight-Swift (KNX), Old Dominion (ODFL), Swift Transportation (SWFT) and Werner (WERN), Paccar (PCAR), Allison Transmission(ALSN), Cummins (CMI) and Volvo (VOLVY).

13:04 EST Uber CEO says 'nothing we can't adjust to' on coronavirus impact

13:03 EST GeoVax Labs provides update on COVID-19 development program - GeoVax Labs provided an update on its development of a vaccine for prevention/control of novel coronavirus disease, COVID-19, caused by SARS-Cov-2 coronavirus. The update was given by GeoVax's Chief Scientific Officer, Farshad Guirakhoo, PhD, during his presentation on emerging infectious diseases entitled "Development of Single Dose Vaccines for Emerging Infectious Diseases Using a Novel MVA Platform" at the World Immunotherapy Congress in San Diego, California. GeoVax is using its GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China. In late January, the Company entered into a letter of intent to begin a collaboration with BravoVax, a vaccine developer in Wuhan, China, to jointly develop a vaccine. Under the arrangement, upon receipt of vaccine candidates from GeoVax, BravoVax will provide testing and manufacturing support, as well as direct interactions with Chinese public health and regulatory authorities.

12:59 EST Uber says hasn't seen major impact from coronavirus outbreak - Says some areas of its business, like Uber Eats, may actually benefit. Says that if coronavirus does turn out to be a crisis, "we are in a far better position than any other company in our space." Comments taken from the Morgan Stanley Technology, Media & Telecom Conference.

12:57 EST Uber rallies 4% to $34.33 during Morgan Stanley conference presentation

12:17 EST Dave & Buster's rises after KKR increases stake - Shares of Dave & Buster's (PLAY) are up about 7% near noon after it was disclosed earlier this morning that funds affiliated with KKR (KKR) increased their stake in the entertainment and restaurant company to 12.7%. "The Reporting Persons or their affiliates also have additional economic exposure to an aggregate of 1,345,493 shares of common stock [...] for a total aggregate economic exposure of the reporting persons and their affiliates to 3,871,293 shares of common stock, representing approximately 12.7% of the outstanding shares of common stock," this morning's filing stated. At time of writing, D&B shares are up $2.23, or 7.4%, to $32.34.

11:42 EST Twilio canceling from events due to coronavirus concerns - Twilio stated in a post to its corporate blog: "Like many of you, we've been monitoring the news about COVID-19, and in an abundance of caution for our customers, employees, and partners, we have decided to cancel our customer events and involvement in third party industry events for the month of March. This action is taken in an abundance of caution for the protection of our community. The canceled events include all of our Twilio Engage + Superclass events, Twilio Talks, Twilio After Hours, and other customer and third-party events...We still plan to move forward with our events in April and beyond, including Enteprise Connect, March 30-April 2, in Orlando, and SIGNAL, May 20-21, in San Francisco. However, we will continue to monitor the situation with updates provided by the World Health Organization and the Center for Disease Control and may modify our schedule based on developments with COVID-19." Reference Link

11:23 EST Santander Bank reduces prime rate to 4.25% - Santander Bank announced that it has lowered its prime rate from 4.75% to 4.25%, effective March 3, 2020.

11:02 EST Bonitas Research issues short report on Jinkosolar, calls equity 'worthless' - In a recently published report, Bonitas Research said it is short JinkoSolar as it thinks its equity is "ultimately worthless." "We believe that JinkoSolar exists for the sole purpose of developing PRC assets with JKS' cash that were disposed to Chairman Li at a significant discount to market. An older vintage of U.S.-listed Chinese fraud, JKS was fattened up with 5 separate equity issuances and US$2B-plus in net debt only to be stripped of value by insiders. This is why JKS, despite its purported profitability, had failed to generate free cash flow or pay shareholders cash dividends. Evidence shows that Chairman Li privatized JKS' most valuable assets for himself, leaving JKS shareholders saddled with debts and construction cost liabilities. [...] Evidence showed that JKS fabricated its 2017 and 2018 financial statements by including US$209M of fake sales to Australia and by omitting US$42M in customs duties that JKS remains liable for in South Africa," the report reads. Reference Link

10:39 EST General Electric transformation is in 'second inning,' CEO says - General Electric CEO Larry Culp is speaking on CNBC.

10:28 EST Brown-Forman sees gross margin down about 200bps for FY20

10:15 EST Brown-Forman: 'Hard to quantify' financial impact of coronavirus right now - Cites "many unknowns."

10:06 EST Centene awarded correctional contracts for medical & behavioral health services - Centene Corporation announced that its subsidiary Centurion has received notice from the Delaware Department of Correction of the Department's intent to award two contracts to Centurion for medical and behavioral health services. Both three-year contracts are expected to commence on April 1, 2020 and include two, two-year renewal options. Under the contracts, Centurion will provide medical services, behavioral healthcare, and substance abuse treatment within four prisons and six community corrections centers across the state. "Centurion is pleased to partner with the Delaware Department of Correction, and we are committed to working with the DOC to improve the medical and behavioral healthcare, and substance use disorder treatment for individuals under DOC custody," said Centurion CEO Steven H. Wheeler. "We look forward to bringing our innovative staffing and care solutions to Delaware's unified state correctional agency."

10:02 EST AM InvestCo signs amendment agreement with Ilva Commissioners - ArcelorMittal announces that AM InvestCo and the Ilva Commissioners signed an amendment to the original lease and purchase agreement for Ilva. The Amendment Agreement outlines the terms for a significant investment by Italian state-sponsored entities into AM InvestCo, thereby forming the basis for an important new partnership between ArcelorMittal and the Italian government. The equity investment by the Italian Government in Ilva, to be captured in an agreement to be executed by 30 November 2020, will be at least equal to AM InvestCo's remaining liabilities against the original purchase price for Ilva. The Amendment Agreement is structured around a new industrial plan for Ilva, which involves investment in lower-carbon steelmaking technologies. The core of the new industrial plan is the construction of a DRI facility to be funded and operated by third party investors and an EAF to be constructed by AM InvestCo. In addition, AM InvestCo and the Ilva Commissioners have entered into a separate settlement agreement whereby AM InvestCo agreed to revoke its notice to withdraw from the original agreement and the Ilva Commissioners agreed to withdraw their request for an injunction, which was scheduled to be heard in the Civil Court of Milan on 6 March 2020. In the event that the Investment Agreement is not executed by 30 November 2020, AM InvestCo has a withdrawal right, subject to an agreed payment. Final closing of the lease and purchase agreement is now scheduled by May 2022, subject to various conditions precedent.

10:00 EST HP Enterprise falls -7.8% - HP Enterprise is down -7.8%, or -98c to $11.61.

10:00 EST Molina Healthcare rises 13.3% - Molina Healthcare is up 13.3%, or $16.27 to $138.70.

10:00 EST Anthem rises 14.6% - Anthem is up 14.6%, or $37.41 to $293.79.

09:47 EST Daily S&P Biotech Bear 3x Shares falls -9.0% - Daily S&P Biotech Bear 3x Shares is down -9.0%, or -$1.22 to $12.37.

09:47 EST Curative Health Services Inc rises 11.6% - Curative Health Services Inc is up 11.6%, or $6.59 to $63.40.

09:47 EST Centene rises 14.0% - Centene is up 14.0%, or $7.54 to $61.58.

09:20 EST Net 1 UEPS appoints Kuben Pillay to board of directors - Net 1 UEPS Technologies announced the appointment of Kuben Pillay as an independent non-employee director of the Company, effective June 1, 2020. He will also serve on the nominating and corporate governance, audit and remuneration committees, effective June 1, 2020. Kuben has most recently served as the non-executive chairman of Cell C Limited from August 2017 to October 2019. Net1's Board will be comprised of two executive and six independent directors once Mr. Pillay's appointment is effective.

09:17 EST Lam Research sees medium-term WFE market at $60B per year - Targets 2023/24 revenue at $14.5B-$15.5B, operating margin 32%-33%, EPS of $30-$32, and free cash flow of 28%-29%. Comments taken from investor presentation slides accompanying the company's investor meeting yesterday. Reference Link

09:16 EST Associated Banc-Corp lowers prime rate to 4.25% - Associated Banc-Corp has decreased the bank's prime rate from 4.75% to 4.25%, effective March 4.

09:15 EST RumbleON in process of assessing damage to facilities in Tennesse from tornadoes - RumbleON announced that it is in the process of assessing the damage sustained to its facilities and inventory in the greater Nashville, Tennessee area due to the tornadoes that struck the area on March 3. Marshall Chesrown, RumbleOn's CEO, and Peter Levy, its COO, were onsite Tuesday morning to implement the company's assessment and recovery plan. RumbleOn maintains insurance coverage for damage to its facilities and inventory, as well as business interruption insurance. The company is in the process of reviewing these coverages with its insurance carriers.

09:13 EST Neovasc targets obtaining CE Mark for TA Tiara by 2021 or earler - The company said, "Eighty-two patients have been treated to date with transapical Tiara, and after extensive analysis of all Clinical data, the company believes there is sufficient evidence from the Tiara I and II clinical studies to support a CE Mark. Management plans to submit for CE Mark under the new European MDR regulations in 2020 and is targeting obtaining a CE Mark for the TA Tiara by 2021 or earlier. Regarding the next generation, transfemoral/trans-septal Tiara, the design has been frozen, and we are on track for clinical trials, including a first-in-human implant, by the end of 2020. Neovasc is targeting the large unmet need for mitral valve regurgitation and optimal treatment will require a variety of treatment options. The TF/TS Tiara features a unique "D shape" which mimics the native anatomy and is designed to avoid left ventricular outflow tract obstruction. Additionally, the TF/TS Tiara features full retrievability of the device after the atrial and ventricular portions of the valve have been deployed, until the point of final release. This key feature should further reduce implant risk for the patient, which combined with longer term functional benefits may provide many mitral valve regurgitation patients a new treatment option."

09:10 EST Evolus calls Medytox comments on ITC case 'speculative' - Evolus provided the following statement: "In several media reports this week, Medytox has made comments on the International Trade Commission case, which Evolus believes are speculative and intended to create confusion in the U.S. market ahead of the ITC Judge's initial determination in June 2020 and the ITC's final determination, which is targeted for October 2020. Importantly, nothing has changed as a result of the media reports from Korea. The ITC Judge will make his own independent decision based upon all the evidence presented at the hearing and through all of the parties' filings. The Judge assigned to the ITC case is not obligated to accept a staff attorney's position on the facts, and it's fairly common for the Judge and the staff attorney to disagree on substantive matters. Evolus and Daewoong remain confident in the strength of our intellectual property and will continue to vigorously defend it through the entirety of the ITC process. In addition, numerous claims have been made in the Korean press regarding settlement discussions related to the ITC proceedings. It is the company's policy to not confirm or comment on settlement discussions."

09:08 EST Emergent BioSolutions selects Axiom Fusion eClinical suite - Axiom Real-Time Metrics announced its engagement with Emergent BioSolutions, a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats.

09:06 EST Twilio appoints Steve Pugh CSO, Glenn Weinstein chief customer officer - Twilio announced the appointment of two executives to its team. Steve Pugh joined the company as its chief security officer, or CSO, to lead Twilio's global trust and security team responsible for corporate, physical and cyber security. Glenn Weinstein joined the company as its chief customer officer responsible for Twilio's technical support, customer success, customer experience, professional services and consulting partners. Pugh will report to CFO, Khozema Shipchandler, and Weinstein reports to COO, George Hu. Pugh is the former chief information security officer of the White House Military Office and has more than 20 years experience in cybersecurity, national security and intelligence. Before Twilio, Weinstein was co-founder of Appirio, a cloud consultancy company.

09:05 EST Campbell Soup says continues to see FY20 CapEx approximately $350M

09:03 EST Nokia, Marvell enter partnership on silicon technology for 5G - Nokia (NOK) and Marvell (MRVL) announced that they are working together to develop leading 5G multi-RAT silicon innovations, including multiple generations of custom silicon and infrastructure processors to further expand the range of Nokia ReefShark chipsets available for 5G solutions. The two companies are developing a new generation of custom system-on-chip and infrastructure processors combining Nokia's differentiated wireless technology with Marvell's industry-leading multi-core Arm processor platforms. These new chipsets are designed to be deployed in several building blocks of the Nokia AirScale radio access solution, as part of Nokia's 5G "Powered by ReefShark" portfolio. By deploying ReefShark, these solutions will benefit from a reduction in size and power consumption, while also seeing a boost to capacity and overall performance.

09:02 EST El Pollo Loco rolls out plant-based chicken alternative system-wide - El Pollo Loco becomes the first national chicken brand in the category to deliver plant-based chicken system-wide with the launch of its new Chickenless Pollo Taco and Burrito. El Pollo Loco bypassed the popular suppliers in the space and instead created its own plant-based protein for the new Chickenless Pollo Taco and Burrito. The recipe blends authentic Mexican flavors in an adobo sauce with a non-GMO 100% soy protein base that mirrors shredded chicken.

08:49 EST Campbell Soup says integration of snacks 'on plan' - Says "actions to simplify and streamline operations, along with initiatives around manufacturing and logistics, will begin to deliver savings in Q3."

08:41 EST Anika Therapeutics appoints David Colleran general counsel - Anika Therapeutics (ANIK) announced the appointment of David Colleran to the newly created position of executive VP, general counsel and corporate secretary. In this new role, Colleran will lead the company's global legal organization, including corporate governance and compliance. Prior to joining Anika, Colleran served as senior VP, general counsel, corporate secretary and chief compliance officer at Insulet (PODD).

08:38 EST iMedia Brands announces 'Cooking with Shaq' on ShopHQ - iMedia Brands announced the debut of its live broadcast program, "Cooking with Shaq", on ShopHQ. The program is part of iMedia's partnership with Authentic Brands Group, Shaquille O'Neal and ShopHQ, and will also include an innovative collection of kitchenware, cookware, and grill products.

08:37 EST Conduent announces software module for Maven to track coronavirus - Conduent announced the availability of a new software module for its disease surveillance and outbreak management platform, Maven, configured to securely track, manage and report on cases of coronavirus. Maven is a software platform currently used by approximately 40 organizations to manage cases of more than 90 communicable diseases. Starting today, organizations can gain access to Conduent's new module to track COVID-19. The platform is specifically designed to support case management, information integration and coordination among epidemiologists, medical professionals and health departments.

08:33 EST YayYo appoints Ramy El-Batrawi as CEO - YayYo has appointed Ramy El-Batrawi as CEO and a member of its board of directors, effective immediately. Boyd Bishop will step down from his role as president and has agreed to serve as a consultant to the Company going forward. El-Batrawi is the original founder of YayYo and served as its CEO until February 2019. El-Batrawi is also the founder of X, LLC, a private investment firm focused on acquiring companies and implementing effective growth strategies. At his request, El-Batrawi will not receive compensation in connection with his appointment as chief executive officer or his service on YayYo's board of directors.

08:32 EST EXL appoints Anita Mahon as EVP, chief growth and strategy officer - EXL (EXLS) announced the appointment of Anita Mahon to the role of EVP, Chief Growth and Strategy Officer. Anita was most recently Vice President, Data, Strategy & Portfolio Officer at IBM Watson Health (IBM), a business unit focused on developing cognitive and data-driven technologies to advance health. Based in New York, she will also serve as a member of EXL's Executive Committee.

08:20 EST General Electric CEO says COVID-19 impact most pronounced in China

08:14 EST NV5 Global awarded $6M contract expansion by NCDPW - NV5 Global announced that it has been awarded $6M for the expansion of two contracts with the Nassau County Department of Public Works in Long Island, New York. The two contracts include a civil engineering and site development design services contract and a construction management and construction inspection contract. Both contracts have a three-year term and are eligible for extensions of up to two years. The expanded relationship is the result of NV5's success in winning multiple task order assignments and the positive contribution of NV5 to NCDPW projects. Assignments under these NCDPW contracts are expected to include engineering design and inspection related to resurfacing of roadways, reconstruction of roadways and drainage systems, reconstruction of county parks, and rehabilitation of highway bridges.

08:11 EST GE CEO sstill sees BioPharma sale closing in Q1

08:10 EST GE CEO says will continue to sell down Baker Hughes stake 'in orderly fashion'

08:08 EST Cellect Biotechnology to acquire all rights to use of Canndoc products - Cellect has approved and entered, subject to definitive agreements, into a commercial binding Letter Of Intent with Canndoc, a pharma grade medical cannabis pioneer, a wholly owned subsidiary of publicly-traded Intercure. Clinical evidence from over 12 years of experience treating Canndoc's patients, primarily in oncology, has shown a reduction in patient opioid consumption. Cellect will acquire from Canndoc all rights to the use of Canndoc products for the reduction of opioid usage, including accumulated data, as well as on-going and pipeline of clinical trials. In addition, Canndoc will supply Cellect, over the course of the next five years, with a minimum of 6 tons of GMP pharma grade cannabis products with a value of $18M. Cellect will have the option to extend the agreement for an additional period of 5 years, until 2029. The products will be distributed and sold on behalf of Cellect by Canndoc' s existing distribution channels. Cellect will issue to Canndoc 1,023,720 ADRs representing 19% of Cellect's share capital on partially diluted basis. In addition to the strategic commercial agreement the companies are considering expanding their collaboration and have signed a non-binding LOI for a full merger. Under preliminary details, Cellect will acquire from Intercure all of Canndoc outstanding shares, in exchange for additional Cellect ADRs to be in total ~95% of the merged company. The proposed merger is subject to definitive agreement, Board approval and customary closing conditions. The parties aim to close such transaction in Q2.

08:08 EST Global Blood Therapeutics announces new employment inducement grants - Global Blood Therapeutics announced that on March 1, 2020, the compensation committee of GBT's board of directors granted four new employees restricted stock units for an aggregate of 15,550 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT's board of directors in January 2017 and amended in June 2019.

08:06 EST General Electric CEO says still has 'work to do' on turnaround

08:04 EST Griffin appoints Gordon DuGan as chairman of the board - Griffin Industrial Realty has appointed Gordon DuGan as a Director and Non-executive Chairman of its Board of Directors and Molly North as Director effective March 3, 2020. DuGan is the former Chairman and CEO of Gramercy Property Trust. North is the President and CEO of Al. Neyer. Frederick "Mike" Danziger, Griffin's former Chairman, will continue to serve as a Director, and Michael Gamzon will remain Griffin's President and CEO, and a Director. In connection with the appointments of Mr. DuGan and Ms. North, Griffin increased the size of its Board of Directors to nine members. Upon his appointment to the Board, Mr. DuGan and Griffin entered into a chairmanship and advisory agreement whereby Mr. DuGan agreed to provide advisory services in addition to his role as Chairman. Mr. DuGan has agreed to advise Griffin on, amongst other items, its growth strategy, including identifying markets, acquisitions and other transactions, recruitment of key personnel, potential capital raising efforts and other general management advice. In connection with Mr. DuGan's appointment as Chairman and execution of the chairmanship and advisory agreement, Mr. DuGan will be entitled to purchase up to an aggregate of $2,500,000 of Griffin's common stock from the Company in a private placement, subject to approval by the Board or a committee thereof. Additionally, Griffin will grant Mr. DuGan options to purchase 100,000 shares of Griffin's stock, as well as the standard option to purchase shares of Griffin's stock awarded to all Directors upon joining the Board. The Advisor Options will vest equally on the third, fourth and fifth anniversaries of the date of grant, subject to Mr. DuGan's continued provision of Advisory Services through the applicable vesting date. The Director Option is fully vested on the date of grant. Due to Mr. DuGan's chairmanship and advisory agreement with the Company, Mr. DuGan is not considered to be an independent director, as defined under The Nasdaq Stock Market LLC rules.

08:03 EST Lipocine's Tlando receives PDUFA date of August 28 - Lipocine announced that the FDA acknowledged receipt of the resubmission of TLANDO New Drug Application, the company's oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. The FDA has assigned a Prescription Drug User Fee Act goal date of August 28. The NDA incorporates the reanalysis of existing data based on written feedback to address the single remaining deficiency discussed in the Post Action Meeting with the FDA.

08:02 EST Griffin board approves plan to pursue conversion to REIT - Griffin Industrial Realty Board of Directors has unanimously approved a plan for the Company to pursue conversion to a Real Estate Investment Trust. This decision is based on the Board's and management's consideration of ways to maximize stockholder value and generate growth opportunities as the Company continues to expand its industrial/warehouse property portfolio in select markets. Griffin, if successful in the conversion process, would plan to elect REIT status with the taxable year beginning January 1, 2021. In accordance with tax rules applicable to REITs, Griffin expects to distribute its accumulated earnings and profits of approximately $14M to $19M to stockholders, to be paid out in a combination of at least 20% in cash and up to 80% in Griffin common stock. The Company intends to distribute substantially all of the E&P Distribution in the fourth quarter of calendar year 2020. The estimated range of the E&P Distribution is based on Griffin's 2019 taxable year results and an estimate of 2020 taxable year performance, but Griffin's actual E&P will vary depending on a number of items, including the occurrence and timing of certain transactions and the Company's actual results. Griffin has completed a preliminary analysis of the REIT requirements and believes it can meet the operational and technical thresholds for qualification as a REIT. These thresholds may include the creation of one or more taxable REIT subsidiaries to own or operate certain portions of its business. In addition, stockholder approval will be required to effect the necessary corporate reorganization, including a provision to establish REIT-related ownership restrictions in Griffin's charter. Latham & Watkins, LLP is advising Griffin on the REIT conversion process. In addition to the E&P Distribution, Griffin expects to incur approximately $1M in one-time costs to support the conversion process. There can be no assurances that Griffin will be successful in its planned conversion and should Griffin fail to complete the conversion process, it will have incurred substantial costs.

07:51 EST Arcturus Therapeutics, Duke-NUS partner to develop coronavirus vaccine - Arcturus Therapeutics and Duke-NUS Medical School announced their partnership to develop a Coronavirus vaccine for Singapore. The development of a COVID-19 vaccine will be based on the Company's STARR technology and will take advantage of a unique platform developed at Duke-NUS allowing rapid screening of vaccines for effectiveness and safety. The STARR Technology platform combines self-replicating RNA with LUNAR, a leading nanoparticle non-viral delivery system, to produce proteins inside the human body. Due to superior immune response and sustained protein expression, Arcturus' STARR Technology is expected to produce a vaccine response at much lower doses compared to traditional mRNA vaccines. This could lead to the ability to treat many more people with a single GMP-manufactured production batch, thereby greatly increasing efficiency and reducing time required to produce sufficient quantities of vaccine for large populations.

07:48 EST RioCan REIT launches Green Bond Framework - RioCan Real Estate Investment Trust announced its Green Bond Framework. RioCan is the first REIT in Canada to establish a Green Bond Framework. RioCan's Green Bond Framework has been reviewed by Sustainalytics, a global leader in providing environmental, social and governance research and analysis. Sustainalytics issued a second party opinion confirming that RioCan's Green Bond Framework aligns with the International Capital Markets Association Green Bond Principles 2018.

07:45 EST Abercrombie & Fitch estimates COVID-19 adverse impact $60M-$80M

07:42 EST Abercrombie & Fitch sees majority of COVID-19 impact occuring in 1H20 - The company said, "As a result of the recent COVID-19 outbreak, the company has taken measures to protect its global associates, customers and business partners and is conforming to local government and global health organizations guidance. This has included the temporary closures of its Shanghai regional home office and of its stores in mainland China and in and around Milan, Italy as well as global travel restrictions. The APAC region contributed less than 10% of fiscal 2019 net sales, with mainland China and China's Hong Kong Special Administrative Region combined representing roughly half of this contribution. Total company manufacturing exposure to China was 22% in fiscal 2019, down from 36% in fiscal 2018, and is planned in the low-teens for fiscal 2020. The company has seen, and expects to continue to see, a direct impact to sales and margin from lost sales in the APAC region and in locations across Europe and North America. The company also anticipates impacts from potential disruption of product deliveries across the global supply chain. The company currently expects the majority of the impact from COVID-19 to occur in the first half. The full year and first quarter outlooks provided below incorporate these estimated impacts. In addition, excluded from the company's outlook are other potential impacts that may result from COVID-19, including, but not limited to, asset impairment charges and deferred tax valuation allowances. Actual results may differ materially from these estimates as the scope of COVID-19 evolves. Despite near-term uncertainties, the company remains confident in its global long-term growth opportunities."

07:40 EST Abercrombie & Fitch reports Q4 comparable sales up 1%

07:38 EST Dollar Tree sees Q1 SSS up low single digits

07:34 EST Campbell Soup: Year-to-date savings of $90M through 1H20 pacing on schedule - In the second quarter of fiscal 2020, Campbell achieved $45M in savings under its multi-year cost savings program, inclusive of Snyder's-Lance synergies, bringing total program-to-date savings to $650M. Year-to-date savings of $90M through the first half of fiscal 2020 are pacing on schedule. As previously announced, the company expects to deliver cumulative annualized savings of $850M by the end of fiscal 2022.

07:31 EST XPO Logistics, Mercedes-Benz sign long-term partnership agreement - XPO Logistics (XPO) has signed a long-term partnership agreement with Mercedes-Benz Parts Logistics (DDAIF) to manage UK parts distribution through an integrated, digitally-managed transportation network. XPO will distribute automotive parts to Mercedes-Benz's UK retail and commercial vehicle dealerships, running over 40 routes daily from the Mercedes-Benz European Logistics Center in Milton Keynes and XPO's overnight-delivery depots in Motherwell, Leigh, Wakefield, Gloucester and Taunton. As part of this partnership, XPO has committed to investing in 42 new trucks that will be dedicated to serving the Mercedes-Benz passenger and commercial vehicle dealer networks. The core fleet will consist mostly of the 2020 International Truck of the Year - the Mercedes-Benz Actros. These heavy-duty trucks will be operated by XPO drivers and managed by a dedicated team of XPO distribution experts using customized technology. The trucks feature intelligent networking with logistics processes, leading fuel efficiency technology from Mercedes-Benz and the innovative MirrorCam digital safety system.

07:28 EST Tower Semiconductor SiGe technology adopted by Renesas for RFIC production - Tower Semiconductor announced that Tower Semiconductor's SiGe BiCMOS platform was selected for the development and production of Renesas Electronics' market-leading beamforming and amplifier RFICs for phased array antenna applications. Phased array antennas or more specifically active electronically scanned arrays have been a staple of the defense industry for over 40 years, but are now rapidly emerging in the commercial marketplace due to the exponentially growing demands for connectivity. These antennas will be critical to the enablement of high data-rate, low latency connectivity in the air, at sea and on the ground, taking advantage of the rapid growth in throughput from existing GEO and emerging non-geostationary LEO/MEO satellite networks.

07:22 EST RedHill Biopharma 'working toward' confirmatory Phase 3 study for BEKINDA - RedHill concluded a positive FDA meeting on the pediatric study plans required to potentially obtain pediatric labeling for RHB-102, in addition to the intended adult labeling. RedHill is currently working toward a confirmatory Phase 3 study to support a potential New Drug Application for RHB-102 for acute gastroenteritis and gastritis, subject to FDA guidance. The confirmatory Phase 3 study will follow the successful completion of a first Phase 3 study for acute gastroenteritis and gastritis with RHB-102, the findings of which were published in JAMA Open Networks in November 2019.

07:21 EST RedHill to initiate enrollment in second arm of Phase 1/2a ABC294640 study in Q1 - RedHill has completed the enrollment of the full cohort of 39 patients evaluable for efficacy in the Phase 2a study evaluating the activity of orally-administered ABC294640 in advanced cholangiocarcinoma. Preliminary data from the open-label Phase 2a study has indicated a signal of activity in a number of subjects with advanced cholangiocarcinoma. RedHill plans to submit this data for presentation at an upcoming scientific meeting. In light of this, and in light of positive data from a pre-clinical program evaluating ABC294640 in combination with additional actives, RedHill has added a second arm to the study, evaluating ABC294640 in combination with hydroxychloroquine, an anti-autophagy agent. Enrollment of patients to the second arm of the Phase 1/2a study is planned to be initiated in the first quarter of 2020. RedHill also plans to add a third arm to the study, evaluating ABC294640 in combination with RHB-107. An investigator-sponsored study with ABC294640 in prostate cancer is planned to be initiated at the Medical University of South Carolina in the coming weeks. The study is supported by a National Cancer Institute grant awarded to MUSC.

07:19 EST Abiomed announces publication of study supporting lower risk for PVAD patients - A study of 21,848 non-emergent, high-risk patients who underwent percutaneous coronary intervention, or PCI, with percutaneous ventricular assist devices, or PVADs, including Impella, demonstrates the PVAD patients had a lower rate of mortality and complications than patients who underwent PCI with intra-aortic balloon pumps, or IABPs. The study, by Al-khadra published in the February 15 print edition of Catheterization & Cardiovascular Interventions. In the analysis, the PVAD cohort was significantly sicker than the IABP cohort. PVAD patients were older and had higher rates of hypertension, diabetes, hyperlipidemia, prior PCI, prior coronary artery bypass graft surgery, anemia, chronic lung disease, liver disease, renal failure and peripheral vascular disease. Investigators obtained their data from the National Inpatient Sampling, or NIS, database, the largest all-payer inpatient care database in the United States. NIS is developed through a partnership with the Agency for Healthcare Research and Quality and contains data on approximately eight million Medicare and private payer hospital stays. The authors disclosed and described in detail the methods for the study population, patient and hospital characteristics and statistical analysis, including linear regression models and propensity score matching. The Al-khadra publication also noted that PVAD patients had a shorter length of stay than IABP patients. This finding is consistent with the PROTECT II randomized controlled trial and multiple other peer-reviewed studies, including the Maini publication in Expert Review of Pharmacoeconomics & Outcomes Research. Maini appraises the findings and conclusions of six publications and found PVADs, specifically Impella 2.5, are associated with reduced hospital length of stay and are cost-effective when compared with IABP.

07:17 EST RedHill Biopharma expects Movantik rights acquisition to close in 1Q20 - In February 2020, RedHill (RFHL) announced that it is acquiring the global rights to Movantik, excluding Europe, Canada and Israel, from AstraZeneca (AZN). The acquisition is expected to close in the first quarter of 2020, subject to certain closing conditions and regulatory clearances. Movantik is a peripherally acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. Movantik generated U.S. net sales of $96 million in 2019. Under the terms of the license agreement, RedHill will make an upfront payment of $52.5 million to AstraZeneca upon closing and a further non-contingent payment of $15 million 18 months post-closing. RedHill will also assume financial responsibility for sales-based royalty and potential milestone payments that AstraZeneca is required to pay to Nektar Therapeutics, the originator of Movantik. AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period. In 2015, AstraZeneca entered into a co-commercialization agreement with Daiichi Sankyo for Movantik in the U.S., which will be transferred to RedHill upon closing of the transaction. Following such transfer, RedHill expects to lead all U.S. commercialization activities for Movantik and will continue to share costs and pay sales-related commissions to Daiichi Sankyo under that agreement.

07:15 EST Cubic division awarded $3M contract from AAV for central mobility platform - Cubic announced its Cubic transportation systems business division, or CTS, was awarded a contract worth more than $3M, from Aachener Verkehrsverbund, or AVV, to deliver a central mobility platform for the City of Aachen, Aachen City Region, District of Duren and the District of Heinsberg in Germany. The new central platform will provide ticketing and additional services to all digital sales channels in the region. It will interface with all sales channels and mobility partners to ensure a consistent and convenient service for the associated transport operators as well as other mobility providers such as car and bike sharing. The scheduled go-live for the first phase of the new platform is September.

07:10 EST Alkermes' schyzophrenia candidate Phase 3 results featured in publication - Alkermes announced the publication of results from the phase 3 ENLIGHTEN-1 clinical trial of ALKS 3831 - olanzapine/samidorphan - in the peer-reviewed publication, Journal of Clinical Psychiatry. ENLIGHTEN-1 was a four-week study evaluating the efficacy, safety and tolerability of ALKS 3831 compared to placebo in 403 patients experiencing an acute exacerbation of schizophrenia. Positive topline data from the ENLIGHTEN-1 study were first reported in June 2017. A New Drug Application for ALKS 3831 is currently under FDA review, with a PDUFA target action date of Nov. 15. ENLIGHTEN-1 is one of two key studies included in the ALKS 3831 ENLIGHTEN clinical development program. ENLIGHTEN-2, the second phase 3 study, assessed weight gain with ALKS 3831 compared to olanzapine over six months. Positive topline data from the ENLIGHTEN-2 study were reported in November 2018.

07:06 EST Marathon Petroleum establishes 2030 greenhouse gas emissions goal - Marathon Petroleum has established a companywide goal to reduce its greenhouse gas emissions per barrel of oil equivalent processed to 30% below 2014 levels by 2030. The company has linked achievement of the goal to its executive compensation program and certain employee programs. "Marathon Petroleum has long been a leader in reducing its GHG emissions intensity, and due to our culture of continual improvement and responsiveness to stakeholder concerns, setting a goal and linking further reduction achievements to our compensation is a logical progression," said MPC Chairman and CEO Gary Heminger. "We have added GHG emissions intensity reduction as one of our sustainability metrics for 2020, along with environmental incidents, safety performance, and process safety." In addition to its GHG emissions intensity reductions, MPC is also committed to further expanding its renewable fuel manufacturing and blending capabilities. Current projects include the conversion of its Dickinson, North Dakota, refinery into a renewable diesel plant at a cost of $470M, and processing of biocrude generated from municipal waste at its Martinez, California, refinery. In addition, MPC is actively working with and investing in Virent, Inc., its wholly owned research and development subsidiary in Madison, Wisconsin, toward the commercialization of Virent's BioForming technology for producing bio-gasoline and bio-jet fuel from various sugars.

07:06 EST Amag Pharmaceuticals announces 2020 key priorities - The company plans to complete successful CEO transition, divest Intrarosa and Vyleesi to align with the new strategic direction, drive continued Feraheme growth, work with the FDA to maintain patient access to Makena , advance ciraparantag and AMAG-423 development programs, pursue ex-U.S. portfolio partnering opportunities and meet or exceed financial guidance.

07:01 EST Amag Pharmaceuticals CMO Julie Krop departing March 31st - AMAG Pharmaceuticals announced changes to its medical development organization. Effective March 31, Julie Krop, Chief Medical Officer, will be leaving the company. As AMAG initiates a search for a permanent CMO, the Board of Directors and management will continue to work closely with the medical development organization on key priorities, including working with the FDA to find a path to retain patient and provider access to Makena and advancing the ciraparantag and AMAG-423 clinical development programs. Additionally, former board member Lesley Russell will provide further, interim expertise as Clinical Consultant, effective immediately. DrRussell has three decades of experience in clinical development and regulatory affairs, and will advise the company during the transition to a new CMO.

06:57 EST New Relic receives FedRAMP authorization - New Relic has received FedRAMP authorization at a moderate impact level. FedRAMP is a government-wide program that provides a standardized approach to security assessment, authorization, and continuous monitoring for cloud products and services.

06:51 EST General Electric sees 'growing' revenue in 2021 - Sees segment margin flat to growing, with free cash flow "up."

06:50 EST General Electric says coronavirus situation is 'fluid,' monitoring closely - Comments taken from GE's 2020 Investor Outlook conference call presentation slides.

06:40 EST GE says further impact from coronavirus not incorporated beyond Q1

06:38 EST GE sees GE Industrial net debt/EBITDA ratio fo less than 2.5x - Compared to 2019, GE's 2020 outlook assumes lower free cash flow and profit from BioPharma due to its planned disposition in the first quarter, subject to regulatory approval, as well as reduced cash from Baker Hughes shareholder dividends. GE expects to offset these effects through performance improvements and reduced nonoperational headwinds. GE's 2020 outlook also assumes the 737 MAX returns to service in mid-2020, in line with Boeing. GE continues to target achieving a GE Industrial net debt/EBITDA ratio of less than 2.5x, as well as a less than 4-to-1 debt-to-equity ratio for GE Capital, in 2020.

06:24 EST Nordstrom says two directors won't stand for re-election - Nordstrom on Tuesday announced changes to its Board of Directors. Current board members Kevin Turner and Gordon Smith have chosen not to seek re-election to the Board at the expiration of their respective terms at the Company's Annual Shareholders Meeting on May 20, 2020. The Board is working with an external executive search firm for director candidates to fill their seats. Additionally, the Board has announced planned changes designed to enhance its corporate governance. This will include reducing the maximum size of the Board from 11 to 10 over the next two years and introducing a 10-year term limit for independent directors.

06:21 EST Newell Brands discloses SEC subpoena relating to sales practices - In a regulatory filing on Tuesday, Newell Brands disclosed that on January 31, 2020, the company received a subpoena from the U.S. Securities and Exchange Commission primarily relating to its sales practices and certain accounting matters during the period from January 1, 2016 to the date of the subpoena. The subpoena followed various informal document requests from the SEC staff, including several requests primarily related to the impairment of goodwill and other intangible assets. The company has cooperated in providing documents and information to the SEC in connection with its requests and intends to continue to do so in connection with the subpoena. The company cannot predict the timing or outcome of this investigation.

06:11 EST Kayne Anderson MLP reports net assets $1.5B as of February 29 - As of February 29, the company's net assets were $1.5B, and its net asset value per share was $11.85. As of February 29, the company's asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 381% and the company's asset coverage ratio under the 1940 Act with respect to total leverage was 250%.

06:08 EST Allergan, Editas Medicine: First patient dosed in BRILLIANCE trial of AGN-151587 - Allergan (AGN) and Editas Medicine (EDIT) announced the treatment of the first patient in the BRILLIANCE clinical trial of AGN-151587 at Oregon Health & Science University Casey Eye Institute. AGN-151587 is an experimental medicine delivered via sub-retinal injection under development for the treatment of Leber congenital amaurosis 10, an inherited form of blindness caused by mutations in the centrosomal protein 290 gene. The BRILLIANCE clinical trial is a Phase 1/2 study to evaluate AGN-151587 for the treatment of patients diagnosed with LCA10 and is the world's first human study of an in vivo, or inside the body, CRISPR genome editing medicine. The trial will assess the safety, tolerability, and efficacy of AGN-151587 in approximately 18 patients with LCA10.

06:02 EST Patterson-UTI reports an average of 121 drilling rigs operating in February - Patterson-UTI reported that for the month of February, the company had an average of 121 drilling rigs operating. For the two months ended February 29, the company had an average of 122 drilling rigs operating.

05:53 EST AT&T says plans to have nationwide 5G coverage by the end of Q2 - As of the end of February, AT&T's 5G network covers more than 80M people and the company plans to have nationwide 5G coverage by the end of the second quarter. Stankey also said that, based on expected 5G growth and HBO Max opportunities, mobility will continue to be the biggest driver of revenue growth and profitability. AT&T also expects FirstNet to contribute to wireless revenue growth, with FirstNet subscriber additions ramping as push-to-talk capabilities and new devices drive growth. The company expects wireless service revenues to grow by more than 2% in 2020. Stankey said the company is still on track for a May launch of HBO Max. He said more than 10M HBO subscribers on AT&T distribution platforms will be offered immediate access to HBO Max at launch. Stankey said AT&T has identified 10 categories of cost initiatives over the short-, mid- and long-term targeting double-digit billions of dollars in gross savings over the next three years.